Chantix effective
This article was originally published in The Tan Sheet
Executive Summary
Continuous smoking cessation rates for four weeks were significantly higher for patients taking varenicline tartrate (Pfizer's Chantix) 1 mg twice daily compared to placebo (48% versus 17.1%), according to a study published in the Archives of Internal Medicine August 14/28. The Pfizer-sponsored, randomized study included 638 smokers between ages 18 to 65 at seven U.S. sites, Mitchell Nides, PhD, et al., say. The researchers compared three dosages of varenicline, bupropion hydrochloride (GlaxoSmithKline's Zyban) and placebo for seven weeks with follow up through week 52. Efficacy was determined by exhaled carbon monoxide tests at weeks 12, 24, and 52, and daily dairies recording the number of cigarettes smoked. Chantix, 1 mg twice daily, "effectively helped subjects quit smoking, with response rates three times higher than those for placebo....Efficacy was maintained in the non-drug treatment phase through week 52," Nides et al. say. FDA approved prescription Chantix in May 1("The Tan Sheet" May 15, 2006, In Brief)...
You may also be interested in...
Rx smoking cessation pill
FDA has approved Pfizer's smoking cessation drug Chantix (varenicline) for prescription use, the agency announces May 11. The drug, which Pfizer originally had intended to market as Champix, is the first nicotine agonist approved by FDA, and the first new Rx medication approved for smoking cessation in more than a decade, according to the firm. Varenicline works by binding to nicotine receptors in the brain, thereby "providing some nicotine effects to ease withdrawal symptoms and...blocking the effects of nicotine from cigarettes if [people] resume smoking," FDA states. Pfizer expects Chantix to launch in the second half of 2006. The firm has stated in the past that it will draw from its Nicorette experience when developing DTC ads for Chantix (1"The Tan Sheet" Feb. 9, 2004, p. 5)...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.